1852 related articles for article (PubMed ID: 15265969)
21. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Moebus V; Jackisch C; Lueck HJ; du Bois A; Thomssen C; Kurbacher C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Kreienberg R; Konecny GE; Untch M
J Clin Oncol; 2010 Jun; 28(17):2874-80. PubMed ID: 20458045
[TBL] [Abstract][Full Text] [Related]
22. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.
Tokuda Y; Tajima T; Narabayashi M; Takeyama K; Watanabe T; Fukutomi T; Chou T; Sano M; Igarashi T; Sasaki Y; Ogura M; Miura S; Okamoto S; Ogita M; Kasai M; Kobayashi T; Fukuda H; Takashima S; Tobinai K; ;
Cancer Sci; 2008 Jan; 99(1):145-51. PubMed ID: 17970786
[TBL] [Abstract][Full Text] [Related]
23. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR; Kröger N; Schmoor C; Krüger W; Möbus V; Frickhofen N; Metzner B; Schultze W; Berdel WE; Koenigsmann M; Thiel E; Wandt H; Possinger K; Trümper L; Kreienberg R; Carstensen M; Schmidt EH; Jänicke F; Schumacher M; Jonat W
J Clin Oncol; 2004 Jun; 22(12):2273-83. PubMed ID: 15111618
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
[TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG;
N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087
[TBL] [Abstract][Full Text] [Related]
28. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
29. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
30. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
[TBL] [Abstract][Full Text] [Related]
31. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
32. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Bonneterre J; Roché H; Kerbrat P; Brémond A; Fumoleau P; Namer M; Goudier MJ; Schraub S; Fargeot P; Chapelle-Marcillac I
J Clin Oncol; 2005 Apr; 23(12):2686-93. PubMed ID: 15837983
[TBL] [Abstract][Full Text] [Related]
33. [Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].
Elling D; Krocker J; Kümmel S; Blohmer J; Lichtenegger W; Kohls A; Heinrich J; Quass J; Breitbach P; Köhler U
Zentralbl Gynakol; 2000; 122(4):207-16. PubMed ID: 10795118
[TBL] [Abstract][Full Text] [Related]
34. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC; Rondón G; Yang Y; Smith TL; Gajewski JL; Donato ML; Shpall EJ; Jones R; Hortobagyi GN; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2004 Nov; 10(11):794-804. PubMed ID: 15505610
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
[TBL] [Abstract][Full Text] [Related]
40. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
